PLYMOUTH MEETING, Pa., July 27 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced new data from preclinical studies of trodusquemine (MSI-1436) for the treatment of obesity. Michael McLane, Ph.D., Vice President, Nonclinical Development, presented "Trodusquemine: A Novel Small Molecule for the Treatment of Obesity and Related Metabolic Disorders," during the CBI 3rd Annual Obesity Drug Development Summit, July 26-27 in Arlington, Va.
